Corrigendum to Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol 2022;234:223-234.

Am J Ophthalmol

The Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, United States.

Published: October 2022

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515063	PMC
http://dx.doi.org/10.1016/j.ajo.2022.07.018	DOI Listing

Publication Analysis

corrigendum phase

phase randomized

randomized controlled

controlled study

study short

short course

course topical

topical recombinant

recombinant human

human nerve

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!